V
31.80
1.55 (5.12%)
| Previous Close | 30.25 |
| Open | 30.09 |
| Volume | 1,003,630 |
| Avg. Volume (3M) | 990,173 |
| Market Cap | 2,478,644,480 |
| Price / Earnings (TTM) | 102.58 |
| Price / Earnings (Forward) | 19.80 |
| Price / Sales | 4.53 |
| Price / Book | 1.73 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | 7.13% |
| Operating Margin (TTM) | 7.03% |
| Diluted EPS (TTM) | 0.420 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Total Debt/Equity (MRQ) | 4.23% |
| Current Ratio (MRQ) | 5.10 |
| Operating Cash Flow (TTM) | 89.42 M |
| Levered Free Cash Flow (TTM) | 76.93 M |
| Return on Assets (TTM) | 1.94% |
| Return on Equity (TTM) | 2.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Veracyte, Inc. | Bearish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.45% |
| % Held by Institutions | 107.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 42.00 (UBS, 32.08%) | Buy |
| Median | 41.00 (28.93%) | |
| Low | 37.00 (Guggenheim, 16.35%) | Buy |
| Average | 40.00 (25.79%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 31.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 May 2025 | 41.00 (28.93%) | Buy | 31.21 |
| UBS | 08 May 2025 | 42.00 (32.08%) | Buy | 31.21 |
| Guggenheim | 09 Apr 2025 | 37.00 (16.35%) | Buy | 32.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 May 2025 | Announcement | Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research |
| 20 May 2025 | Announcement | Veracyte to Participate in Upcoming Investor Conferences |
| 07 May 2025 | Announcement | Veracyte Announces First Quarter 2025 Financial Results |
| 25 Apr 2025 | Announcement | Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer |
| 22 Apr 2025 | Announcement | Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting |
| 21 Apr 2025 | Announcement | Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release |
| 16 Apr 2025 | Announcement | Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |